SCHEMBL6411734

SCHEMBL6411734

CC1CCN(C(=O)CCN2C(=O)c3ccccc3C(C(=O)NCc3ccccc3)C2c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
SCN9A Q15858 6/20 0.41
SCN5A Q14524 5/20 0.41
KCNH2 Q12809 3/20 0.41
HSD17B10 Q99714 1/20 0.40
TACR1 P25103 2/20 0.40
TSHR P16473 2/20 0.40
FFAR1 O14842 2/20 0.40
NPSR1 Q6W5P4 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6413158 0.93 SCN9A (0.41) CCR2ALDH1A1KDM4EMAPTHTT
SCHEMBL6411904 0.90 SCN9A (0.41) CCR2ALDH1A1KDM4EMAPTHTT
SCHEMBL6411373 0.90 SCN9A (0.47) CCR2ALDH1A1KDM4EMAPTHTT
SCHEMBL6415209 0.89 SCN9A (0.41) CCR2ALDH1A1KDM4EMAPTHTT
SCHEMBL6410919 0.84 TSHR (0.45) ALDH1A1KDM4EMAPTHTTSCN9A
SCHEMBL6411735 0.83 KCNA5 (0.43) CCR2SCN9ASCN5AKCNH2HSD17B10
SCHEMBL6416277 0.83 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHTTKCNH2
SCHEMBL6414420 0.82 ALDH1A1 (0.43) ALDH1A1KDM4EMAPTHTTKCNH2
SCHEMBL6414870 0.82 ALDH1A1 (0.48) ALDH1A1KDM4EMAPTHTTTSHR
SCHEMBL6418322 0.81 HSD17B10 (0.55) ALDH1A1KDM4EMAPTHTTSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD CCR2 2916/4885ALDH1A1 1368/4885KDM4E 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.